Bristol-Myers Squibb Company (BMY) Earnings History
Annual and quarterly earnings data from 1989 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 56.8% | 20.0% | -18.5% |
| 2023 | 56.3% | 18.8% | 17.8% |
| 2022 | 57.4% | 20.1% | 13.7% |
| 2021 | 57.7% | 20.6% | 15.1% |
| 2020 | 51.0% | 10.6% | -21.2% |
Download Data
Export BMY earnings history in CSV or JSON format
Free sign-in required to download data
Bristol-Myers Squibb Company (BMY) Earnings Overview
As of February 28, 2026, Bristol-Myers Squibb Company (BMY) reported trailing twelve-month net income of $6.04B, reflecting -2.1% year-over-year growth. The company earned $2.96 per diluted share over the past four quarters, with a net profit margin of -0.2%.
Looking at the long-term picture, BMY's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.61B in fiscal 2009.
Bristol-Myers Squibb Company maintains positive profitability with a gross margin of 0.6%, operating margin of 0.2%, and net margin of -0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including LLY ($18.41B net income, 0.2% margin), JNJ ($25.12B net income, 0.2% margin), AZN ($10.22B net income, 0.2% margin), BMY has room to improve margins relative to the peer group. Compare BMY vs LLY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8.95B | -211.5% | $9.66B | $-4.41 | -18.5% | 20.0% |
| 2023 | $8.03B | +26.8% | $8.47B | $3.86 | 17.8% | 18.8% |
| 2022 | $6.33B | -9.5% | $9.27B | $2.95 | 13.7% | 20.1% |
| 2021 | $6.99B | +177.8% | $9.54B | $3.12 | 15.1% | 20.6% |
| 2020 | -$8.99B | -361.6% | $4.49B | $-3.98 | -21.2% | 10.6% |
| 2019 | $3.44B | -30.1% | $6.44B | $2.01 | 13.2% | 24.6% |
| 2018 | $4.92B | +388.6% | $6.39B | $3.03 | 21.8% | 28.3% |
| 2017 | $1.01B | -77.4% | $5.24B | $0.61 | 4.8% | 25.2% |
| 2016 | $4.46B | +184.8% | $5.18B | $2.65 | 22.9% | 26.7% |
| 2015 | $1.56B | -21.9% | $3.94B | $0.97 | 9.5% | 23.8% |
See BMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BMY vs AGIO
See how BMY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BMY growing earnings?
BMY EPS of $2.96 reflects slowing growth at -2.1%, below the 5-year CAGR of N/A. TTM net income is $6.0B. Expansion rate has moderated.
What are BMY's profit margins?
Bristol-Myers Squibb Company net margin is -0.2%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are BMY's earnings?
BMY earnings data spans 1989-2024. The current earnings trend is -2.1% YoY. Historical data enables comparison across business cycles.